T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
A vaccine for hepatitis C has eluded scientists for more than 30 years, for several reasons. For one, the virus that causes the disease comes in many genetic forms, complicating the creation of a widely effective vaccine.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors.
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.
Cutaneous T-cell lymphoma (CTCL) is an incurable, rare cancer of skin-homing T cells that is highly disfiguring and lethal at advanced stages.
Blocking a protein chain reaction makes childhood leukemia cells more sensitive to an existing targeted treatment, a new study shows.
When the immune system fails and assaults the body’s own components, autoimmune disorders develop.
Every kind of T cell has a job to do. A healthy immune system makes sure no T cell oversteps.
We speak to Dr. Chao Ma, one of the speakers at SLAS 2022, about his groundbreaking 'leukemia-on-a-chip' technology and its future within therapy resistance.
The omicron variant can partly evade the antibody response provided by vaccination or infection with previous variants of SARS-CoV-2.
Endometrial cancer is the most common cancer of the female reproductive system. Patients who have active immune responses against cancer cells tend to have better outcomes, but much of what is known focuses on only one type of immune cell called T cells.
A new study by researchers from the University of Pennsylvania shows that experimental immunotherapy can temporarily reprogram the immune cells of patients.
In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.
Recent research suggested that grouping of pathogen-recognizing proteins on immune T cells might be vital in pinpointing if an individual had an infection in the past.
More than 40,000 allogeneic hematopoietic stem cell transplants are carried out worldwide every year, mostly for patients suffering from leukemia or other diseases of the hematopoietic system.
Can T-cell tests be used to determine whether people have had COVID-19? Scientists at Uppsala University and Karolinska Institutet have jointly analysed this issue under the aegis of the COMMUNITY study at Danderyd Hospital. Their study is published in the scientific journal PLOS ONE.
AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.
Cold Spring Harbor Laboratory Press (CSHLP) announced the release of T-Cell Memory, available on its website in hardcover and eBook formats.
Extremely premature infants are at a high risk for brain damage. Researchers at the University of Vienna and the Medical University of Vienna have now found possible targets for the early treatment of such damage outside the brain: Bacteria in the gut of premature infants may play a key role.
A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers.